Cancer Immunotherapy Market Size, Share, Growth Analysis, By Product Type(Monoclonal Antibodies [Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies], Vaccines [Prophylactic Vaccines), By Cancer Type(Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer), By End-User(Hospitals, Clinics & Others), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35I2296 | Region: Global | Published Date: September, 2024
Pages: 157 |Tables: 120 |Figures: 69

Cancer Immunotherapy Market Insights

Global Cancer Immunotherapy Market size was valued at USD 125.4 billion in 2022 and is poised to grow from USD 135.93 billion in 2023 to USD 259.16 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).

The rising prevalence of target therapy in place of traditional therapy, increasing demand for mABs, and emergence of various biosimilars around the globe are the key factors anticipated to drive the growth of the global market during the forecast period. These drugs are mainly designed and created to boost the body’s immune response to fight against cancer with high dependence on the discovery of molecules, is also projected to have positive impact on the global Cancer Immunotherapy market growth and demand over the coming years.

Furthermore, growing approval from Food and Drug administration such as PD-1 and CTLA-4 checkpoint inhibitors for the treatment of melanoma and non-small cell lung cancer are further expected to boost the global cancer immunotherapy market growth throughout the forecast period. For instance, in May 2021, the US Food and Drug Administration has approved the Amgen’s LUMAKRAS for the better treatment of patients suffering from KRAS G12C, that involves mutated locally advanced or metastatic cell lung cancer. It is the first ever treatment for NSCLC in the world.

US Cancer Immunotherapy Market is poised to grow at a sustainable CAGR for the next forecast year. 

Market snapshot - 2024-2031

Global Market Size

USD 39.05 billion

Largest Segment

Monoclonal antibodies

Fastest Growth

Monoclonal antibodies

Growth Rate

9.6% CAGR

Global Cancer Immunotherapy Market ($ Bn)
Country Share for North America Region (%)

To get more reports on the above market click here to Buy The Report

Cancer Immunotherapy Market Segmental Analysis

Global Cancer Immunotherapy Market is segmented by Product Type, Application, End user, and region. Based on Product Type, the market is segmented into Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, and Other Cancer Types. Based on End user, the market is segmented into Hospitals, and Clinics & Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Cancer Immunotherapy Market Analysis by Product

By product, the monoclonal bodies segment dominated the market and accounted for a significant market share in 2021. An extensive rise in the research & development activities of monoclonal antibodies has paved the way for new revenue generation to major companies to provide oncology therapeutics. The rising R&D activities have resulting in introduction to mABs, which have various features such as adaptive immunity, antibody dependent cellular toxicity, and antigen specificity due to which, the segment market is anticipated to have a significant growth over the forecast period.

In addition, immunomodulators segment is projected to grow at fastest CAGR over the forecast period owing to high efficiency and accuracy of immunomodulatory drugs. Moreover, increased focus of major market players on introducing various types of novel techniques, is also likely to propel the growth of the segment over the coming years.    

Cancer Immunotherapy Market Analysis by Cancer Type

By cancer type, the lung cancer segment held the largest market share in 2021, and is set to continue its dominance throughout the forecast period. Rising popularity of several types of harmful products like E-cigarettes is fueling the number of lung cancer patients around the globe. According to the World Health Organization, cancer is a leading cause for the deaths worldwide, with a number of around 10 million deaths in 2020, in which 1.80 million deaths cause by lung cancer around the globe.

Furthermore, the melanoma segment expected to grow at significant growth rate during the forecast period that is simply attributed to the development of several new products, rising number of FDA approvals, and high research & development activities in this field.

Global Cancer Immunotherapy Market By Product

To get detailed analysis on other segments, Request For Free Sample Report

Cancer Immunotherapy Market Regional Insights

Globally, North America dominated the market with a healthy Cancer Immunotherapy market share in 2021 due to the rising incidence of diseases, adoption to high technology devices, and growing geriatric population. Additionally, growing number of biotechnology companies and continuously rising development activities coupled with the high consumer income, are some other factors projected to drive the growth of the market in the region over the coming years.

Furthermore, Asia Pacific is witnessing fastest CAGR during the forecast period owing to introduction to new and advanced immunotherapy drugs in countries like India and China with increasing number of clinical trials in the region. Moreover, rising government efforts to improve the healthcare infrastructure and product development especially in emerging economies such as India, China, and Brazil, are also likely to boost the demand for cancer immunotherapy services in the region.

Global Cancer Immunotherapy Market By Region
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Cancer Immunotherapy Market Dynamics

Cancer Immunotherapy Market Drivers

High Efficacy of Immunotherapy to Boost Market Growth

  • Increase in the adoption of immunotherapy treatment over others like radiation therapy and chemotherapies, having more side-effects is the major factor expected to drive the growth of the global cancer immunotherapy market over the forecast period. The former therapies are completely based on destroying cancer cells by irradiation or surgery, the use of these therapies is often limited because they are estimated to kill several healthy cells ae well. Hence, various end-use industries such as hospitals and surgical centers are moving towards immunotherapy treatment, as it enhances the body’s own immunity with the help of man-made proteins, which is fostering the growth of the global market.
    Besides, there are several cases where cancer patients are beyond the conventional diagnosis and herein patients avail immunotherapy to counter the spread of cancer. In addition, there are solid examples of positive clinical trial results for advanced or metastatic cancer patients.

Cancer Immunotherapy Market Restraints

Huge Investments for R&D to Hamper Market Growth

  • High manufacturing cost and high price for end-user as well is the major factor anticipated to hamper the growth of the global cancer immunotherapy market over the forecast period. Enhancement and development in treatment requires a very large amount of resources and high investment, which is expected to slow down the growth of the market in the coming years.
    Lack of medical access in remote areas and geographical challenges are likely to limit the awareness for cancer immunotherapies.

Request Free Customization of this report to help us to meet your business objectives.

Cancer Immunotherapy Market Competitive Landscape

Global cancer immunotherapy market is highly competitive with the existence of several large pool players operating around the globe. The major players of the global market are focusing on few business developing strategies including high investment in research & development activities, increasing product innovation, strategic partnerships, and collaborations for the expansion of their geographical presence and strengthen their market position among competitors.

Cancer Immunotherapy Market Top Player’s Company Profiles

  • Amgen Inc. (US) 
  • AstraZeneca (UK/Sweden)  
  • Bayer AG (Germany)  
  • Bristol-Myers Squibb (US)  
  • Eli Lilly and Company (US)  
  • Janssen Global Services, LLC (Johnson & Johnson) (US)  
  • Merck & Co., Inc. (US)  
  • Novartis (Switzerland)  
  • Pfizer Inc. (US)  
  • F. Hoffmann-La Roche Ltd (Switzerland)  
  • Gilead Sciences, Inc. (US)  
  • GlaxoSmithKline plc (UK)  
  • AbbVie Inc. (US)  
  • Regeneron Pharmaceuticals, Inc. (US)  
  • Adaptimmune Therapeutics plc (UK)  
  • Incyte Corporation (US)  
  • Bluebird bio, Inc. (US)  
  • BioNTech SE (Germany)  
  • Immunocore Limited (UK)  
  • CureVac N.V. (Germany)  
  • BeiGene, Ltd. (China)  
  • Zymeworks Inc. (Canada)

Cancer Immunotherapy Market Recent Developments

  • In June 2022, The Janssen Pharmaceutical Company of Johnson & Johnson announced that the U.S. Food and Drug Administration has granted CARVYKTI for the treatment of adult patients with the process of relapsed refractory multiple myeloma.
  • In April 2021, the US Food and Drug Administration has approved the Opdivo, in combination with several types of chemotherapy, for the initial treatment process of patients, who are suffering from advanced and metastatic cancer as well as esophageal adenocarcinoma. This is the first and only immunotherapy received FDA-approval for treatment of gastric cancer.

Cancer Immunotherapy Key Market Trends

  • Approval of New Drug Class to Surge Cancer Immunotherapy Market Growth: Immunotherapies in development are expected to offer more treatment options and better outcomes than existing therapies. Newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to target receptors associated with multiple myeloma, are poised to shape the market's future.
  • Novel Research to Reduce Research Costs: Ongoing research on similar drugs aimed at reducing side effects is expected to drive market growth. Furthermore, the approval of PD-1 and CTLA-4 checkpoint inhibitors for melanoma and Non-Small Cell Lung Cancer (NSCLC) has boosted market growth. The approval of novel immunotherapy drug forms, such as vaccines and adjuvants, is increasing. Furthermore, more immunotherapies, such as immunomodulators and CAR T-cell therapy, are being tested for improved outcomes. These new approvals and ongoing research are expected to drive market growth over the forecast period.

Cancer Immunotherapy Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected utilizing Primary Exploratory Research backed by the robust Secondary Desk research.

According to our analysis, the global cancer immunotherapy market is projected to have a strong growth during the forecast period owing to high technology advancements, increased consumer disposable income, and growing prevalence of cancer around the globe. In addition, lower side-effects less likely to disease return, and ability to work when other treatment don’t are also expected to fuel the growth of the market in the coming years. However, some issues associated with cancer immunotherapy like swelling, weight gain, and heart palpitations along with the high treatment cost are likely to hinder the growth of the global market over the forecast period.

Report Metric Details
Market size value in 2022 USD 125.4 billion
Market size value in 2031 USD 259.16 billion
Growth Rate 8.4%
Base year 2023
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Product Type
    • Monoclonal Antibodies [Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies], Vaccines [Prophylactic Vaccines, Therapeutic Vaccines], Checkpoint Inhibitors [Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4), Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)], Cell Therapies [Chimeric Antigen Receptor (CAR) T Cell Therapy, Dendritic Cells], Immunomodulators [Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf), Interferons (IFN), Interleukins (IL), Oncolytic Virus (Immunotherapy, Immunity as an Obstacle, Immunity as an Ally, Approved Products & Clinical Trails)]
  • Cancer Type
    • Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, Other Cancer Types
  • End-User
    • Hospitals, Clinics & Others
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Amgen Inc. (US) 
  • AstraZeneca (UK/Sweden)  
  • Bayer AG (Germany)  
  • Bristol-Myers Squibb (US)  
  • Eli Lilly and Company (US)  
  • Janssen Global Services, LLC (Johnson & Johnson) (US)  
  • Merck & Co., Inc. (US)  
  • Novartis (Switzerland)  
  • Pfizer Inc. (US)  
  • F. Hoffmann-La Roche Ltd (Switzerland)  
  • Gilead Sciences, Inc. (US)  
  • GlaxoSmithKline plc (UK)  
  • AbbVie Inc. (US)  
  • Regeneron Pharmaceuticals, Inc. (US)  
  • Adaptimmune Therapeutics plc (UK)  
  • Incyte Corporation (US)  
  • Bluebird bio, Inc. (US)  
  • BioNTech SE (Germany)  
  • Immunocore Limited (UK)  
  • CureVac N.V. (Germany)  
  • BeiGene, Ltd. (China)  
  • Zymeworks Inc. (Canada)
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Cancer Immunotherapy Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Cancer Immunotherapy Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Cancer Immunotherapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Immunotherapy Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Immunotherapy Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Cancer Immunotherapy Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW

REQUEST FOR SAMPLE

Want to customize this report?
REQUEST FREE CUSTOMIZATION

FAQs

Global Cancer Immunotherapy Market size was valued at USD 125.4 billion in 2022 and is poised to grow from USD 135.93 billion in 2023 to USD 259.16 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).

Global cancer immunotherapy market is highly competitive with the existence of several large pool players operating around the globe. The major players of the global market are focusing on few business developing strategies including high investment in research & development activities, increasing product innovation, strategic partnerships, and collaborations for the expansion of their geographical presence and strengthen their market position among competitors. 'Amgen Inc. (US) ', 'AstraZeneca (UK/Sweden)  ', 'Bayer AG (Germany)  ', 'Bristol-Myers Squibb (US)  ', 'Eli Lilly and Company (US)  ', 'Janssen Global Services, LLC (Johnson & Johnson) (US)  ', 'Merck & Co., Inc. (US)  ', 'Novartis (Switzerland)  ', 'Pfizer Inc. (US)  ', 'F. Hoffmann-La Roche Ltd (Switzerland)  ', 'Gilead Sciences, Inc. (US)  ', 'GlaxoSmithKline plc (UK)  ', 'AbbVie Inc. (US)  ', 'Regeneron Pharmaceuticals, Inc. (US)  ', 'Adaptimmune Therapeutics plc (UK)  ', 'Incyte Corporation (US)  ', 'Bluebird bio, Inc. (US)  ', 'BioNTech SE (Germany)  ', 'Immunocore Limited (UK)  ', 'CureVac N.V. (Germany)  ', 'BeiGene, Ltd. (China)  ', 'Zymeworks Inc. (Canada)'

Increase in the adoption of immunotherapy treatment over others like radiation therapy and chemotherapies, having more side-effects is the major factor expected to drive the growth of the global cancer immunotherapy market over the forecast period. The former therapies are completely based on destroying cancer cells by irradiation or surgery, the use of these therapies is often limited because they are estimated to kill several healthy cells ae well. Hence, various end-use industries such as hospitals and surgical centers are moving towards immunotherapy treatment, as it enhances the body’s own immunity with the help of man-made proteins, which is fostering the growth of the global market.Besides, there are several cases where cancer patients are beyond the conventional diagnosis and herein patients avail immunotherapy to counter the spread of cancer. In addition, there are solid examples of positive clinical trial results for advanced or metastatic cancer patients.

Approval of New Drug Class to Surge Cancer Immunotherapy Market Growth: Immunotherapies in development are expected to offer more treatment options and better outcomes than existing therapies. Newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to target receptors associated with multiple myeloma, are poised to shape the market's future.

Globally, North America dominated the market with a healthy Cancer Immunotherapy market share in 2021 due to the rising incidence of diseases, adoption to high technology devices, and growing geriatric population. Additionally, growing number of biotechnology companies and continuously rising development activities coupled with the high consumer income, are some other factors projected to drive the growth of the market in the region over the coming years.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Cancer Immunotherapy Market

Report ID: SQMIG35I2296

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE